Chronic kidney disease affects more than 850 million people worldwide, making it one of the most prevalent non-communicable diseases of our era. Yet among its many complications, one of the most complex is a condition called chronic kidney disease-mineral and bone disorder, or CKD-MBD. This is not simply a problem of weak bones. It is a systemic disruption touching the skeleton, the cardiovascular system, and the delicate biochemical balance that keeps the body functioning. As kidney function declines, the body’s ability to regulate key minerals — calcium, phosphate, and vitamin D — begins to unravel, triggering a cascade of changes that can accelerate cardiovascular disease and increase mortality risk.
The International Society of Nephrology has placed CKD-MBD among its core educational and research priorities, supporting the development of international clinical guidelines and funding real-world studies that track how this condition is managed across healthcare systems. This article offers a comprehensive overview of what CKD-MBD is, why it matters, how it is diagnosed, and what current evidence says about management — written for patients, caregivers, and healthcare professionals alike.
What Is CKD-MBD? Defining a Systemic Disorder
Chronic kidney disease-mineral and bone disorder is an umbrella term introduced by the Kidney Disease: Improving Global Outcomes (KDIGO) initiative to describe a triad of interconnected abnormalities that emerge as kidney function progressively declines. These three elements are:
- Mineral metabolism disturbances — abnormal levels of calcium, phosphate, parathyroid hormone (PTH), and vitamin D in the blood
- Bone disease — structural and functional changes in bone tissue, including reduced density, altered turnover, and increased fracture risk
- Vascular and soft tissue calcification — the abnormal deposition of calcium-phosphate complexes in blood vessel walls and other soft tissues, which stiffens arteries and impairs cardiovascular function
These three components do not occur in isolation — they influence and amplify one another in a self-perpetuating cycle that begins early in the course of CKD and worsens as kidney function deteriorates. Understanding this cycle is essential to understanding why CKD-MBD is so clinically significant.
The Physiology Behind the Disorder: How Kidney Decline Disrupts Mineral Balance
The Kidney’s Role in Mineral Regulation
Healthy kidneys perform a wide range of regulatory functions beyond filtering waste from the blood. They activate vitamin D, regulate phosphate excretion, and respond to signals from the parathyroid glands to maintain calcium homeostasis. When the kidneys lose functional nephrons — the microscopic filtering units — all of these processes begin to fail in a predictable and interconnected sequence.
Phosphate Retention and the Early Warning Signal
One of the earliest detectable changes in CKD-MBD is a rise in fibroblast growth factor 23, or FGF23. This protein is produced by bone cells in response to rising phosphate levels and serves as a hormonal signal that tells the kidneys to excrete more phosphate and suppress vitamin D activation. In early CKD, FGF23 levels rise substantially — sometimes a hundred-fold or more — as the body tries to compensate for the kidneys’ declining ability to eliminate phosphate.
This compensatory mechanism was brought into focus by research published in the New England Journal of Medicine in 2008 by Gutierrez and colleagues, who demonstrated that elevated FGF23 was independently associated with mortality in patients beginning hemodialysis. This finding established FGF23 not merely as a phosphate-regulating hormone but as a pathogenic mediator with direct effects on patient outcomes. ISN (International Society of Nephrology) has since supported efforts to integrate FGF23 monitoring into clinical practice, recognizing its value as an early biomarker of CKD-MBD progression.
Vitamin D Deficiency and Secondary Hyperparathyroidism
As CKD advances, the kidneys lose the ability to convert vitamin D into its active form, calcitriol. This leads to vitamin D deficiency, which reduces calcium absorption from the gut. Falling calcium levels in the blood trigger the parathyroid glands — four small glands located behind the thyroid — to secrete parathyroid hormone (PTH) in increasing amounts. This condition, known as secondary hyperparathyroidism, causes the parathyroid glands to enlarge over time and can become refractory to medical treatment in advanced stages.
Elevated PTH stimulates bone resorption — the breakdown of bone tissue — to release calcium into the bloodstream. Over time, this leads to osteitis fibrosa cystica: a high bone turnover state characterized by structural weakening and increased fracture risk. In contrast, some patients develop adynamic bone disease, a low-turnover state linked to PTH oversuppression, which carries its own fracture and cardiovascular risks.
FGF23 and the Heart: A Connection That Changed Clinical Thinking
One of the most significant advances in CKD-MBD research concerned the relationship between FGF23 and cardiovascular disease. A landmark study by Faul and colleagues (Journal of Clinical Investigation, 2011) demonstrated that FGF23 directly induces pathological hypertrophy of the left ventricle through FGF receptor-dependent MAPK signaling in heart muscle cells — independently of FGF23’s roles in phosphate regulation and vitamin D suppression.
Left ventricular hypertrophy is a major risk factor for heart failure and sudden cardiac death. Its high prevalence in CKD patients had long been recognized without a fully satisfying biological explanation. The FGF23-to-heart pathway provided that explanation and opened a new rationale for aggressive phosphate control in CKD management. For the International Society of Nephrology, this research underscored the importance of treating CKD-MBD to protect the heart, not just the bones.
Vascular Calcification: The Silent Cardiovascular Threat
Vascular calcification — the hardening of blood vessel walls due to mineral deposits — is one of the most clinically dangerous manifestations of CKD-MBD. In the general population, arterial calcification is primarily a late-stage feature of atherosclerosis. In CKD patients, however, it occurs earlier, progresses faster, and is driven by mechanisms that differ substantially from those in the general population.
Elevated phosphate plays a central role. High phosphate promotes the transformation of vascular smooth muscle cells into a bone-like phenotype, causing them to deposit calcium-phosphate crystals within arterial walls. This stiffens the arteries, raises systolic blood pressure, impairs coronary flow, and increases cardiac workload — a convergence of risks explaining why cardiovascular disease is the leading cause of death in dialysis patients.
Observational evidence from large studies, including populations within the SHARP trial, has confirmed that vascular calcification strongly predicts cardiovascular events and death in CKD. The EVOLVE trial (Chertow et al., New England Journal of Medicine, 2012) evaluated cinacalcet for secondary hyperparathyroidism in hemodialysis patients and demonstrated significant reductions in FGF23 and vascular calcification markers. However, the primary composite cardiovascular endpoint did not reach statistical significance in the intention-to-treat analysis — highlighting the complexity of translating biochemical improvements into measurable reductions in hard clinical outcomes.
Diagnosing CKD-MBD: What Clinicians Monitor
The diagnosis and monitoring of CKD-MBD relies on a combination of laboratory tests, imaging studies, and in some cases bone biopsy. The KDIGO 2017 Clinical Practice Guideline Update for CKD-MBD — developed with support from ISN and published in Kidney International Supplements — provides the principal evidence-based framework for clinical decision-making.
Key Laboratory Parameters
| Parameter | Clinical Significance | Monitoring Frequency in CKD Stage 3–5 |
|---|---|---|
| Serum phosphate | Elevated levels drive vascular calcification and FGF23 rise | Every 6–12 months (stage 3); every 1–3 months (stage 5D) |
| Serum calcium | Hypocalcemia triggers PTH secretion; hypercalcemia worsens calcification | Every 6–12 months (stage 3); every 1–3 months (stage 5D) |
| Parathyroid hormone (PTH) | Elevated PTH indicates secondary hyperparathyroidism; excess suppression causes adynamic bone disease | Every 6–12 months (stage 3–4); every 3 months (stage 5D) |
| 25-hydroxyvitamin D | Deficiency contributes to secondary hyperparathyroidism | At baseline; periodically thereafter |
| Alkaline phosphatase | Bone-specific ALP reflects bone turnover activity | Every 12 months (or with PTH changes) |
| FGF23 | Early marker of phosphate dysregulation; associated with cardiovascular risk | Not yet universally standardized in routine practice |
Imaging and Bone Assessment
Lateral abdominal X-ray and echocardiography are commonly used to detect and quantify vascular calcification. Bone mineral density measurement by dual-energy X-ray absorptiometry (DXA) can identify patients at fracture risk, though its interpretation in CKD requires caution because the nature of bone disease in this population is heterogeneous. Bone biopsy with histomorphometry, while invasive, remains the gold standard for distinguishing different subtypes of CKD bone disease and is reserved for cases where clinical decision-making is uncertain.
Management Strategies: From Diet to Dialysis
Dietary Phosphate Restriction
Reducing dietary phosphate intake is a foundational strategy. Phosphate is abundant in protein-rich foods and is also added as a preservative to many processed foods. Organic phosphate from plant-based sources is less bioavailable than inorganic phosphate in food additives — making the source of dietary phosphate, not just the quantity, clinically relevant. Dietitians play a key role in helping CKD patients navigate these distinctions without compromising nutritional adequacy.
Phosphate Binders
When dietary restriction is insufficient, phosphate binders reduce intestinal phosphate absorption. Available agents include calcium-based binders (calcium carbonate, calcium acetate), non-calcium-based binders (sevelamer carbonate, lanthanum carbonate), and iron-based binders. Calcium-based binders are effective and affordable but can contribute to hypercalcemia and vascular calcification in excess, shifting prescribing toward non-calcium alternatives in higher-risk patients. The International Society of Nephrology has highlighted a critical gap here: while binders reliably lower serum phosphate, robust evidence linking them to reduced cardiovascular endpoints remains limited.
Vitamin D and Its Analogs
Vitamin D supplementation in CKD can take several forms. Nutritional vitamin D (cholecalciferol or ergocalciferol) addresses baseline 25-hydroxyvitamin D deficiency. Active vitamin D analogs — calcitriol, alfacalcidol, paricalcitol, and doxercalciferol — directly suppress PTH and are used when secondary hyperparathyroidism requires more aggressive management, though they carry risks of hypercalcemia and hyperphosphatemia requiring careful monitoring.
Calcimimetics
Calcimimetics such as cinacalcet sensitize the calcium-sensing receptor on parathyroid cells, effectively reducing PTH secretion without raising calcium or phosphate levels — an advantage over vitamin D analogs in patients already prone to hypercalcemia. Etelcalcetide, a newer intravenous calcimimetic, has demonstrated efficacy in reducing PTH in hemodialysis patients and offers a convenient administration route during dialysis sessions. Current KDIGO guidance and ISN recommendations emphasize individualized decision-making when selecting between these agents, taking into account patient tolerance, biochemical profile, and treatment goals.
Optimal PTH Targets: An Ongoing Debate
Despite decades of clinical experience, the question of what PTH level to target in dialysis patients remains one of the most contested areas in CKD-MBD management. Current KDIGO guidelines suggest maintaining PTH levels within approximately two to nine times the upper limit of normal for the assay used, but the evidence base for precise targets is weak. Both excessive PTH elevation and excessive suppression carry risks — the former leading to high-turnover bone disease and cardiovascular damage, the latter to adynamic bone disease and calcification. ISN (International Society of Nephrology) continues to advocate for high-quality clinical trials that can resolve this uncertainty and provide clearer guidance to clinicians worldwide.
Real-World Evidence: What DOPPS Tells Us
The Dialysis Outcomes and Practice Patterns Study (DOPPS) is one of the most important sources of real-world data on CKD-MBD management. Supported by ISN and a network of international partners, DOPPS collects longitudinal data from dialysis facilities across more than 20 countries, enabling comparisons of clinical practices, biochemical targets, treatment patterns, and patient outcomes at a global scale.
DOPPS data have repeatedly shown wide variation in CKD-MBD management across countries — in the use of phosphate binders, vitamin D analogs, calcimimetics, and in the biochemical targets pursued. These variations often correlate with differences in healthcare systems, drug availability, and reimbursement policies. By identifying practice patterns associated with better outcomes, DOPPS provides a valuable feedback loop that informs guideline updates globally. For the International Society of Nephrology, DOPPS represents a model of how international collaboration generates clinically actionable evidence in real-world nephrology practice.
Special Populations: Children and Transplant Recipients
Children with CKD face particular challenges because mineral metabolism is critical for normal growth and skeletal development. Secondary hyperparathyroidism in pediatric CKD can cause growth retardation, skeletal deformity, and impaired bone mineralization. Target ranges and treatment thresholds differ from adults, and the long-term consequences of early mineral dysregulation remain an active area of research.
Kidney transplantation does not immediately resolve CKD-MBD. Persisting hyperparathyroidism can cause post-transplant hypercalcemia and accelerated bone loss, partly driven by immunosuppressive corticosteroids. FGF23 levels typically fall after successful transplantation, but recovery trajectories vary widely, requiring ongoing monitoring and individualized management.
The Role of ISN in Advancing Global CKD-MBD Care
The International Society of Nephrology occupies a central position in shaping how CKD-MBD is understood and managed globally. Through participation in KDIGO guideline working groups, support for DOPPS, and educational programs targeting nephrologists in low- and middle-income countries, ISN translates scientific advances into practical clinical tools accessible across healthcare systems.
A persistent challenge is that many interventions discussed here — newer phosphate binders, calcimimetics, FGF23 assays — remain unavailable or unaffordable across significant parts of the world. ISN’s global advocacy includes pushing for equitable access to essential nephrology medications and diagnostics, recognizing that guideline-
concordant care can only become universal if the tools to deliver it are universally accessible.
Conclusion: A Complex Challenge Requiring a Comprehensive Response
CKD-associated mineral and bone disorder is a striking example of how a single organ’s dysfunction can reverberate through multiple body systems. The disruption of mineral metabolism in declining kidneys does not simply threaten the skeleton — it sends pathological signals to the heart, stiffens the arteries, and raises the risk of premature death in ways not fully appreciated until recently. The identification of FGF23 as a direct cardiac toxin, the characterization of vascular calcification as an actively regulated process, and the recognition that PTH management involves genuine clinical trade-offs have all transformed nephrology practice in the past two decades.
Yet important questions remain unanswered. Optimal PTH targets in dialysis patients are still debated. The cardiovascular benefit of phosphate binders beyond biochemical effects has not been established in randomized trials. The clinical role of FGF23 measurement is still evolving. These gaps represent priorities for future research that the International Society of Nephrology is actively supporting through guideline development, global registries, and capacity-building in underserved regions. For patients living with CKD, advances in CKD-MBD management represent one of the most promising frontiers in improving both quality and length of life.